Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.
The observational study showed delays to diagnosis reduced the chances of identifying pathogens and generally led to poorer outcomes.
A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners.
The startup plans to launch research-use diagnostic tests this year and support customers wishing to build custom assays.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
The system will enable testing direct from a tube of blood using peptide nucleic acids-based methods to improve specificity.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.